Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07171515
Enrolling by invitation Observational

Development & Clinical Application of K-PaC Registry Version 2.0

NCT07171515 · tracked via the Priya Life Science South Korea tracker
Sponsor
National Cancer Center, Korea
Phase
Observational
Started
2023-01-02
Last updated
2025-09-12

Condition(s) studied

Pancreatic Cancer

Study summary

Development and clinical use of pancreatic cancer registry

* Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029
* Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of pancreatic cancer Exclusion Criteria: * In cases where medical record review is not feasible

Primary outcome measure(s)

  • Development and clinical use of a pancreatic cancer registry — From initial diagnosis to death
    Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Trial sites (1)

FacilityCityRegionStatus
National Cancer Center Goyang Gyeonggido

More National Cancer Center, Korea trials in South Korea

Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy Enrolling by invitation
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04) Recruiting
Patients With High-grade Pancreatic Neuroendocrine Tumors Enrolling by invitation
Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication Active, not recruiting
CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) Active, not recruiting

Other trials for the same condition

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer Starting soon
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer Active, not recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07171515 on ClinicalTrials.gov ↗ ← All trials in South Korea